SEARCH

SEARCH BY CITATION

References

  • 1
    Shaikhibrahim Z, Braun M, Nikolov P et al. Rearrangement of the ETS genes ETV-1, ETV-4, ETV-5, and ELK-4 is a clonal event during prostate cancer progression. Hum Pathol 2012; 43: 19101916
  • 2
    Huang L, Schauer IG, Zhang J et al. The oncogenic gene fusion TMPRSS2:ERG is not a diagnostic or prognostic marker for ovarian cancer. Int J Clin Exp Pathol 2011; 4: 644650
  • 3
    Truong M, Yang B, Jarrard DF. Toward the detection of prostate cancer in urine: a critical analysis. J Urol 2013; 189: 422429
  • 4
    Pettersson A, Graff RE, Bauer SR et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012; 21: 14971509
  • 5
    Young A, Palanisamy N, Siddiqui J et al. Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. Am J Clin Pathol 2012; 138, 685696
  • 6
    Qu X, Randhawa G, Friedman C et al. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer. Cancer Genet 2013; 206: 111
  • 7
    Smit FP, Salagierski M, Jannink S, Schalken JA. High-resolution ERG-expression profiling on Genechip exon 1.0 ST arrays in primary and castration-resistant prostate cancer. BJU Int 2013; 111: 836842